Alentis Therapeutics
Alentis Therapeutics is a clinical-stage biotech company developing first-in-class anti-Claudin-1 antibodies and ADCs for cancer and fibrosis. Its pipeline includes oncology candidates such as ALE.P02/ALE.P03 and the fibrosis program Lixudebart (ALE.F02).
Company facts
- Founded
- 2019
- Employees
- 67
- Headquarters
- Switzerland
- CEO
- Mark Pruzanski
About
Alentis Therapeutics is a clinical-stage biotechnology company pioneering first-in-class antibody-drug conjugates (ADCs) and antibodies targeting Claudin-1 (CLDN1) for oncology and multi-organ fibrosis. CLDN1 is a previously unexploited target that plays a key role in the pathology of cancer and fibrotic disease. Alent…
Open positions
(Senior) Manager, CMC Program Lead
About this position The CMC Program Lead supports the development and execution of the CMC strategy for Alentis pipeline products, ensuring that CMC activities are aligned with overall program objectives and clinical…